TNBC: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Triple-Negative Breast Cancer}} | |||
== | == Overview == | ||
TNBC | [[File:TNBC_(2000-2002).svg|thumb|right|Diagram illustrating the prevalence of TNBC in breast cancer cases.]] | ||
'''Triple-Negative Breast Cancer''' (TNBC) is a subtype of [[breast cancer]] that is characterized by the absence of three common receptors known to fuel most breast cancer growth: [[estrogen receptor]] (ER), [[progesterone receptor]] (PR), and [[human epidermal growth factor receptor 2]] (HER2). This means that TNBC does not respond to hormonal therapy or therapies that target HER2 receptors, making it more challenging to treat. | |||
== | == Characteristics == | ||
TNBC | TNBC is known for its aggressive nature and poorer prognosis compared to other types of breast cancer. It tends to grow and spread more quickly, and it is more likely to have spread at the time it is found. TNBC is more common in younger women, particularly those under the age of 40, and is more prevalent in African American women and women with a [[BRCA1]] gene mutation. | ||
==Diagnosis== | == Diagnosis == | ||
The diagnosis of TNBC is | The diagnosis of TNBC is confirmed through a combination of [[mammography]], [[ultrasound]], and [[biopsy]]. During the biopsy, a sample of the tumor is tested for the presence of ER, PR, and HER2 receptors. The absence of these receptors confirms the diagnosis of TNBC. | ||
==Treatment== | == Treatment == | ||
[[File:TNBC_(2000-2002).svg|thumb|left|Graph showing the survival rates of TNBC compared to other breast cancer types.]] | |||
Treatment options for TNBC are limited compared to other breast cancer types. The primary treatment is [[chemotherapy]], which may be administered before surgery (neoadjuvant chemotherapy) to shrink the tumor or after surgery (adjuvant chemotherapy) to eliminate any remaining cancer cells. Surgery options include [[lumpectomy]] or [[mastectomy]], depending on the size and location of the tumor. | |||
==Prognosis== | == Prognosis == | ||
The prognosis for TNBC is generally poorer than for other types of breast cancer | The prognosis for TNBC is generally poorer than for other types of breast cancer due to its aggressive nature and limited treatment options. However, the response to chemotherapy can be quite good, and some patients achieve complete remission. Ongoing research is focused on finding new targeted therapies and immunotherapies to improve outcomes for TNBC patients. | ||
==Research== | == Research and Future Directions == | ||
Research into | Research into TNBC is ongoing, with a focus on understanding the molecular and genetic basis of the disease. Studies are exploring the role of [[immunotherapy]], [[PARP inhibitors]], and other targeted therapies in treating TNBC. Clinical trials are crucial for developing new treatment strategies and improving survival rates. | ||
== Related pages == | |||
* [[Breast cancer]] | |||
* [[Chemotherapy]] | |||
* [[Mastectomy]] | |||
* [[BRCA1]] | |||
[[Category:Breast cancer]] | [[Category:Breast cancer]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
Latest revision as of 03:31, 13 February 2025
Overview[edit]
.svg)
Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that is characterized by the absence of three common receptors known to fuel most breast cancer growth: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This means that TNBC does not respond to hormonal therapy or therapies that target HER2 receptors, making it more challenging to treat.
Characteristics[edit]
TNBC is known for its aggressive nature and poorer prognosis compared to other types of breast cancer. It tends to grow and spread more quickly, and it is more likely to have spread at the time it is found. TNBC is more common in younger women, particularly those under the age of 40, and is more prevalent in African American women and women with a BRCA1 gene mutation.
Diagnosis[edit]
The diagnosis of TNBC is confirmed through a combination of mammography, ultrasound, and biopsy. During the biopsy, a sample of the tumor is tested for the presence of ER, PR, and HER2 receptors. The absence of these receptors confirms the diagnosis of TNBC.
Treatment[edit]
Treatment options for TNBC are limited compared to other breast cancer types. The primary treatment is chemotherapy, which may be administered before surgery (neoadjuvant chemotherapy) to shrink the tumor or after surgery (adjuvant chemotherapy) to eliminate any remaining cancer cells. Surgery options include lumpectomy or mastectomy, depending on the size and location of the tumor.
Prognosis[edit]
The prognosis for TNBC is generally poorer than for other types of breast cancer due to its aggressive nature and limited treatment options. However, the response to chemotherapy can be quite good, and some patients achieve complete remission. Ongoing research is focused on finding new targeted therapies and immunotherapies to improve outcomes for TNBC patients.
Research and Future Directions[edit]
Research into TNBC is ongoing, with a focus on understanding the molecular and genetic basis of the disease. Studies are exploring the role of immunotherapy, PARP inhibitors, and other targeted therapies in treating TNBC. Clinical trials are crucial for developing new treatment strategies and improving survival rates.
